A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer.
Fruquintinib|Irinotecan|Capecitabine|Gastrointestinal Tumours
DEVICE: fruquintinib|DRUG: Irinotecan|DRUG: Capecitabine
Progression-free Survival (PFS), PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first., one year
Objective Response Rate (ORR), ORR, determined using RECIST v1.1, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment., one year|Disease Control Rate (DCR), Determined using RECIST v1.1 criteria., one year
This is a real-world observational study of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with advanced colorectal cancer..The purpose of the study is exploring the real-world efficacy and safety of fruquintinib in combination with irinotecan and capecitabine for the second-line treatment of patients with metastatic colorectal adenocarcinoma.